Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis

Summary

This Phase 2a study is designed to evaluate the safety and tolerability of multiple subcutaneous (SC) doses of BG9924, administered in a cohort dose-escalation fashion, in patients with active rheumatoid arthritis (RA) who have had an inadequate response to therapy with disease-modifying anti rheumatic drugs (DMARDs) and who may have undergone anti-TNF therapy. This study will assist with dose selection for further planned Phase 2 studies.

Timeline

Start

2005-11

Primary completion

2007-05

Completion

2007-05

Drugs

Indications